Promising early data suggest patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1, which was well tolerated Following efforts to optimize allogeneic CAR-T therapy, Poseida is presenting a new data analysis